• Affiliate Assistant Professor, Global Health
  • Director, HPV Vaccine Programs, Center for Vaccine Innovation and Access, PATH
Photo of Scott Lamontagne

PATH
Center for Vaccine Innovation and Access: Policy, Access and Introduction functional area
2201 Westlake Avenue, Suite 200
Seattle, WA 98121
United States

Phone Number: 
206-285-3500
Select from the following:
Biography 

D. Scott LaMontagne, PhD, MPH, FRSPH, CS, is an epidemiologist and director of HPV vaccine programs at PATH. He is Principal Investigator for the Single-dose HPV Vaccine Evaluation Consortium, and manages PATH's technical assistance team for country introductions of HPV vaccine. He has authored and co-authored numerous papers on the clinical and operational aspects of HPV vaccine delivery in developing countries and is a recognized international expert in HPV vaccine delivery and evaluation in low-resource settings. Dr. LaMontagne has over 20 years of experience in infectious disease surveillance, operations and implementation research, public health program implementation, monitoring and evaluation, and project management for government and nongovernmental agencies at local, state, and national levels in developed and developing countries. He is a specialist in surveillance and epidemiology of human papillomavirus, Chlamydia trachomatis, tuberculosis, and sexually transmitted infections.

Education 
  • PhD (Middlesex University)
  • MPH (Yale University)
  • BA (University of Washington)
Languages 
  • Japanese
Health Topics 
  • Adult Mortality
  • Cervical Cancer
  • Child and Adolescent Health (incl. Pediatrics)
  • Cost-Effectiveness
  • Delivery Logistics
  • Epidemiology
  • Health Policy
  • HPV
  • Immunizations
  • Implementation Science
  • Operations Research
  • STDs (other than HIV)
DGH Centers, Programs and Initiatives and Affiliated Organizations 
Expertise 

Surveillance and epidemiology of TB and STI's

Publications 

Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake. Vaccine. 2018 Mar 23. doi: 10.1016/j.vaccine.2018.02.003.

LaMontagne DS, Gallagher KE, Watson-Jones D. Why has HPV vaccine uptake lagged: a contextual reframing of vaccine introduction. HPV World 2017 Sep; 1(19):10-12.

LaMontagne DS, Bloem PJN, Brotherton JML, Gallagher KE, Badiane O, Ndiaye C. Progress in HPV vaccination in low and lower-middle income countries. International Journal of Obstetrics & Gynecology 2017; 138(S1): 7-14.

Gallagher KE, Howard N, Kabakama S, Griffiths UK, Mounier-Jack S, Feletto M, LaMontagne DS, Burchett HED, Watson-Jones D. Lessons learnt from human papillomavirus vaccination in low- and middle-income countries. Public Library of Science (PLoS) One 2017; online 2 June 2017. https://doi.org/10.1371/journal.pone.0177773

LaMontagne DS, Cernushi T, Yabuku A, Bloem P, Watson-Jones D, Kim J. Chapter 15. In: Bundy DAP, de Silva N, Horton SE, Jamison DT, and Patton GC, eds. Disease Control Priorities. 3rd edn. Volume 8: child and adolescent health and development. Washington, D.C.: World Bank; 2018.